Make Informed Investment Decisions with Affordable Access to Experts
Discussing the Potential of Eryaspase (GRASPA) as a Second-Line Treatment in Combination with Chemotherapy for Metastatic Pancreatic CancerTicker(s): ERYP.PA, HALO
Name: Dr Safi Shahda - MD
Institution: Indiana University
- GI Oncologist whose clinical practice and research focuses on pancreatic cancer.
- PI for several investigator-initiated and other forms (cooperative, pharma trials) and is familiar with the PHASE 2B study of Eryaspace presented at ESMO.
- Actively treats over 20 patients with metastatic pancreatic and over a dozen of localized and locally advanced patients.
How many patients do you currently treat with metastatic pancreatic cancer?Added By: joe_mccann
What is your view of the Eryaspase (Graspa) approach using L-asparaginase encapsulated in red blood cells to target pancreatic cancer?Added By: joe_mccann
On a scale of 1-10, how excited are you for Eryaspase in this indication for your patients?Added By: joe_mccann
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.